. The prevalence of the Factor V Leiden mutation in Japanese diabetic and non-diabetic subjects Anti-ganglioside GM1 antibody and distal symmetric "diabetic polyneuropathy" with dominant motor features Dear Sir, The prevailing hypothesis of the pathogenesis of chronic diabetic complications is that hyperglycaemia initiates complex metabolic perturbations, which result in pathologic changes in various organs, including the peripheral nervous system. This was amply supported by the Diabetes Control and Complications Trial (DCCT) wherein near normoglycaemia reduced the risk for development of complications [1] . However, once neuropathy is established it proceeds inexorably and cannot be reversed by near-normal glycaemia, for example that achieved by pancreatic transplantation [2, 3] . This could be explained by the fact that neuropathy is a heterogeneous disorder with a multipiicity of aetiologies acting through vascular, immunologic, and metabolic factors [4, 5] , as well as deficient neurotropic support that may also be involved in the progression of neurologic deficit in diabetic patients [4] [5] [6] . Activation of immune effectors may be another mechanism capable of causing neuropathy or perpetuating it, once established, by a variety of mechanisms. Immunopathologic studies have revealed the presence of antibodies (Ab) and complement in the peripheral nerves of patients with distal symmetric polyneuropathy (DSPN), as well as increased numbers of cytotoxic T lymphocytes [7, 8] . These findings support the concept of immune system involvement in the pathogenesis of diabetic neuropathy, in addition to the metabolic and microvascular abnormalities.
To further investigate immune phenomena in diabetic neuropathy, we screened a group of 67 consecutive patients with both diabetes and neuropathy for antibodies against various neuronal antigens, including sulfoglucuronyl paragloboside, sulfatide, neuronal nuclear antigen, myelin associated glycoprotein and the gangliosides: GM1; asialo GM1; and GDlb. We have previously shown that 88% of patients with diabetic neuropathy have phospholipid antibodies in their serum which correlated with sensory loss [9] . In this study we were particularly interested in neuropathy characterized by a predominance of motor features. The neurologic evaluation consisted of the assessment of neuropathy symptoms and disability score (all modified from that of Dyck and colleagues [10] ), motor strength using the medical research council (MRC) scale for motor disability, quantitative sensory testing (QST) and electrophysiologic measurements [11] . Of the neuronal antibodies tested, only GM1 Ab was significantly elevated. Raised titres of anti-ganglioside GM1 antibody (GM1 Ab) (range from 14 to 152 EIA units, normal < 10 EIA units) were found in 14 patients (20.8 %). The duration of neuropathy, duration of diabetes and HbA1c results were similar in antibody Ab positive and Ab negative groups (Table  1) . Motor disability score was significantly higher in the GM1 Ab positive patients as compared to Ab negative individuals (6.5 + 1.5 vs 2.0 + 0.8,p < 0.01), indicating a more severe motor deficit in patients with a raised GM1 Ab titre. There was no direct correlation between antibody titre and nerve disability scores. The magnitude of the sensory deficit, measured by symptom score, sensory disability score and QST, was similar in the two groups. We also did not find a significant difference between the two groups in the electrophysiologic parameters tested (data not shown).
GM1 Ab were found in sera of patients with insulin-dependent diabetes (IDDM) and patients with non-insulin-dependent diabetes (NIDDM). This indicates that neuroimmunological abnormalities are not specific for the type of diabetes, but are associated with the polyneuropathy itself. It is not surprising that patients with NIDDM, as well as those with IDDM, present with neuroimmunological disturbances, since several other non-diabetic, immune-mediated peripheral neuropathies could occur in people with diabetes. For example, chronic inflammatory demyelinating polyneuropathy occurs more frequently in diabetes than the general population [12] .
There are however, several possible explanations for our observations. It could be that these two phenomena, DSPN and raised GM1 Ab titre, occur in diabetic patients independently. Second, GM1 Ab may be an epiphenomenon associated with motor nerve damage, without a direct role in its pathogenesis. Lastly, it is possible that in some patients GM1 Ab are involved in motor nerve destruction and are an indicator of the pathogenic immune process. A number of observations already in the literature suggest that GM1 Ab have pathogenic potential in vitro and in vivo, mainly in the immune-mediated motor neuropathies [13, 14] . These motor neuropathies respond favourably to various immunotherapeutic regimens. In their case report, Krendel et al. [12] suggested that predominantly motor diabetic neuropathy in diabetes may also respond to immunointervention. Our finding suggests that a proportion of patients with predominantly motor signs and symptoms may be GM1 Ab positive and therefore are candidates for immune therapies.
We also propose a prospective study of the markers of the immune system activation in patients with DSPN as a first step in the full scientific evaluation of these interesting observations.
Yours sincerely, Z. Milicevic, E G. Newlon, A. I. Vinik G. L. Pittenger, K. B. Stansberry,
